Possible transmission of parvovirus B19 from intravenous immune globulin.
To look for genetic changes in human parvovirus B19 that might be associated with chronic infection, we sequenced B19 DNA obtained from serum specimens collected over an approximately 1-year period from a patient with systemic vasculitis. A comparison of the nucleotide sequences of the VP1/VP2 gene from four specimens revealed an abrupt change in the B19 genotype that coincided with initiation of intravenous immune globulin (IVIG) therapy. We suspect that one or more of the lots of IVIG administered to the patient were contaminated with B19. If true, this finding suggests that investigators must be careful in linking B19 infection to disease based on detection of B19 DNA in persons who have received multiple unit blood products.
Erdman
D D
DD
Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Georgia 30333, USA. dde1@cdc.gov
Anderson
B C
BC
Török
T J
TJ
Finkel
T H
TH
Anderson
L J
LJ
D000914:Antibodies, Viral / Q000097:blood; D002213:Capsid / Q000235:genetics; D036022:Capsid Proteins; D002675:Child, Preschool; D004279:DNA, Viral; D004340:Drug Contamination; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D008297:Male; D030361:Papillomavirus Infections / Q000097:blood / Q000276:immunology / Q000635:transmission*; D016732:Parvovirus B19, Human / Q000235:genetics / Q000302:isolation & purification; D014657:Vasculitis / Q000097:blood / Q000276:immunology / Q000821:virology
D000914:Antibodies, Viral; D036022:Capsid Proteins; D004279:DNA, Viral; D016756:Immunoglobulins, Intravenous; C095547:capsid protein VP1, parvovirus B19; C095548:capsid protein VP2, parvovirus B19